| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 6, 2024 | Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring) | A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a markete... |
| Apr 5, 2023 | Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect | New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settings
/EIN News/ -- FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”),... |
| Mar 10, 2023 | Arch Therapeutics’ AC5 Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services | The new code represents a key milestone for the commercialization of AC5 Advanced Wound System in doctors’ offices and other outpatient settings
Arch Therapeutics, a marketer and developer of novel self-assembling wound care and biosurgical... |
| Jan 17, 2023 | Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange | /EIN News/ -- FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, t... |
| Oct 11, 2022 | Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall | FRAMINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that two abstracts ... |
| Sep 16, 2022 | Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange | FRAMINGHAM, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding... |
| Jul 7, 2022 | Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing | FRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a... |
| Jun 22, 2022 | Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel | FRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding ... |
| May 9, 2022 | Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring | FRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that the third interv... |
| Apr 13, 2022 | Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring | FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical c... |
| Apr 4, 2022 | Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring | FRAMINGHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical c... |
| Mar 14, 2022 | Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System | FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced it has entered into... |
| Jan 12, 2022 | Arch Therapeutics : Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
Arch Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Cl... |
| Jan 6, 2022 | Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-234811
PROSPECTUS SUPPLEMENT NO. 7 DATED JANUARY 4, 2022
TO
PROSPECTUS DATED FEBRUARY 8, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 36,366,691 Shares of Common Stock... |
| Jan 6, 2022 | Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities | FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced a study of its propr... |
| Jan 4, 2022 | Arch Therapeutics Announces Appointment of Guy Fish to the Board | FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced the appointment of G... |
| Jan 4, 2022 | Arch Therapeutics Announces Appointment of Guy Fish to the Board | Brings Broad Industry Experience in Strategy and Execution
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care an... |
| Dec 13, 2021 | Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System | FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that in partnership ... |
| Dec 1, 2021 | Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program | Renowned Expert Dr. Christopher Gauland Shares Insights on Treating DFUs and Success with AC5® Advanced Wound System
FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a mar... |
| Nov 1, 2021 | Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC) | FRAMINGHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, presented at the Symposium on Advanc... |
| Nov 1, 2021 | Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC) | FRAMINGHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, presented at the Symposium on Advanc... |
| Oct 25, 2021 | Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall | FRAMINGHAM, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that it will be pres... |
| Oct 18, 2021 | Arch Therapeutics Launches Experts in Wound Care Program | FRAMINGHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that it has launched... |
| Oct 18, 2021 | Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-234811
PROSPECTUS SUPPLEMENT NO. 6 DATED OCTOBER 18, 2021
TO
PROSPECTUS DATED FEBRUARY 8, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 36,366,691 Shares of Common Stoc... |
| Oct 13, 2021 | Arch Therapeutics Provides Corporate Update | 90-Day Report Card for Commercialization Effort
FRAMINGHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgic... |
| Oct 13, 2021 | Arch Therapeutics Provides Corporate Update | 90-Day Report Card for Commercialization Effort
FRAMINGHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgic... |
| Oct 6, 2021 | Arch Therapeutics to Present at the LD Micro Main Event | FRAMINGHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, will be featured as a presenting com... |
| Sep 2, 2021 | Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-234811
PROSPECTUS SUPPLEMENT NO. 4 DATED SEPTEMBER 2, 2021
TO
PROSPECTUS DATED FEBRUARY 8, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 36,366,691 Shares of Common Sto... |
| Jul 7, 2021 | Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021 | FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcomin... |
| Jun 5, 2021 | Arch Therapeutics : Quarterly report pursuant to Section 13 or 15(d) | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
Commission File Number: 00... |
| Jun 5, 2021 | Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-253588
PROSPECTUS SUPPLEMENT NO. 2 DATED MAY 6, 2021
TO
PROSPECTUS DATED MARCH 10, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 82,589,497 Shares of Common Stock
This ... |
| Jun 2, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021 | FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually... |
| May 6, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics : Quarterly report pursuant to Section 13 or 15(d) | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
Commission File Number: 00... |
| May 6, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-253588
PROSPECTUS SUPPLEMENT NO. 2 DATED MAY 6, 2021
TO
PROSPECTUS DATED MARCH 10, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 82,589,497 Shares of Common Stock
This ... |
| May 3, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer | FRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abr... |
| Apr 27, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics to Present AC5® Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) | FRAMINGHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case report abst... |
| Apr 19, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics : Prospectus filed pursuant to Rule 424(b)(3) | Filed Pursuant to Rule 424(b)(3)
Registration No. 333-253588
PROSPECTUS SUPPLEMENT NO. 1 DATED APRIL 19, 2021
TO
PROSPECTUS DATED MARCH 10, 2021
(AS SUPPLEMENTED)
ARCH THERAPEUTICS, INC.
PROSPECTUS
Up to 82,589,497 Shares of Common Stock
Th... |
| Apr 19, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results | FRAMINGHAM, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in ... |
| Mar 2, 2021 | Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021 | FRAMINGHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devi... |
| Feb 18, 2021 | Arch Therapeutics Announces Closing of $6.9 Million Private Placement | FRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced it has closed on the previously ann... |
| Feb 13, 2021 | ARCH THERAPEUTICS, INC.
Arch Therapeutics : Quarterly report pursuant to Section 13 or 15(d) | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2020
Commission File Number:... |
| Feb 13, 2021 | Arch Therapeutics : Quarterly report pursuant to Section 13 or 15(d) | UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2020
Commission File Number:... |
| Feb 12, 2021 | Arch Therapeutics Announces $6.9 Million Private Placement | FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into securities... |
| Nov 10, 2020 | ARCH THERAPEUTICS, INC.
Arch Raises Approximately $1.1 Million with Convertible Note Issuance | FRAMINGHAM, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announces that it has raised ap... |
| Nov 10, 2020 | Arch Raises Approximately $1.1 Million with Convertible Note Issuance | FRAMINGHAM, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announces that it has raised ap... |
| Jun 6, 2020 | ARCH THERAPEUTICS, INC.
Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice | FRAMINGHAM, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, announces that it has raised $1.4M from long-te... |
